Illumina’s CEO Jacob Thaysen projects a return to steady annual growth by 2027, despite facing significant headwinds including a Chinese sales ban on sequencers and disruptions from U.S. trade tensions. The company adjusted 2025 revenue guidance downward but maintains confidence in expanding beyond genomics into fields like epigenetics and proteomics. Funding uncertainties in academia pose risks, but recent proposals for National Institutes of Health budget increases offer some optimism.